COVID-19:

How We're Keeping You Safe | What Patients & Families Need to Know

A photo of Daniel Lovell.

Associate Director, Division of Rheumatology

Professor, UC Department of Pediatrics

513-636-4676

513-636-5990

Board Certified

Best Doctors logo

My Biography & Research

Clinical Interests

Diagnostic evaluation and ongoing care of children with all pediatric onset rheumatic diseases

Research Interests

Performance of clinical trials in children with rheumatic diseases; clinical trials methodology; mentoring of junior faculty

Academic Affiliation

Professor, UC Department of Pediatrics

Divisions

Rheumatology, Lupus, Rheumatology

My Locations

My Education

MD: University of Kansas, Kansas City, KS, 1978.

MPH: University of Texas School of Public Health, Houston, TX, 1982.

Residency: Children's Mercy Hospital, Kansas City, KS.

Fellowship: Baylor College of Medicine, Houston, TX.

Certification: Pediatrics, 1984; Pediatric Rheumatology, 1992.

My Publications

Timing matters: Real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis. Huang, B; Qiu, T; Chen, C; Zhang, Y; Seid, M; Lovell, D; Brunner, HI; Morgan, EM; PCATS, . RMD Open. 2020; 6:e001091-e001091.

Immunome perturbation is present in patients with juvenile idiopathic arthritis who are in remission and will relapse upon anti-TNFα withdrawal. Leong, JY; Chen, P; Yeo, JG; Ally, F; Chua, C; Hazirah, SN; Poh, SL; Pan, L; Lai, L; Lee, ES C; et al. Annals of the Rheumatic Diseases. 2019; 78:1712-1721.

Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis. Utz, VM; Bulas, S; Lopper, S; Fenchel, M; Sa, T; Mehta, M; Ash, D; Lovell, DJ; Kaufman, AH. Pediatric Rheumatology Online Journal. 2019; 17.

Severe autoinflammation in 4 patients with C-terminal variants in cell division control protein 42 homolog (CDC42) successfully treated with IL-1β inhibition. Gernez, Y; de Jesus, AA; Alsaleem, H; Macaubas, C; Roy, A; Lovell, D; Jagadeesh, KA; Alehashemi, S; Erdman, L; Grimley, M; et al. Journal of Allergy and Clinical Immunology. 2019; 144:1122-1125.e6.

Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. Morgan, EM; Munro, JE; Horonjeff, J; Horgan, B; Shea, B; Feldman, BM; Clairman, H; III, BC O; Thornhill, S; Strand, V; et al. The Journal of rheumatology. 2019; 46:1006-1013.

2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Angeles-Han, ST; Ringold, S; Beukelman, T; Lovell, D; Cuello, CA; Becker, ML; Colbert, RA; Feldman, BM; Holland, GN; Ferguson, PJ; et al. Arthritis and Rheumatology. 2019; 71:864-877.

2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Angeles-Han, ST; Ringold, S; Beukelman, T; Lovell, D; Cuello, CA; Becker, ML; Colbert, RA; Feldman, BM; Holland, GN; Ferguson, PJ; et al. Arthritis Care and Research. 2019; 71:703-716.

2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Ringold, S; Angeles-Han, ST; Beukelman, T; Lovell, D; Cuello, CA; Becker, ML; Colbert, RA; Feldman, BM; Ferguson, PJ; Gewanter, H; et al. Arthritis Care and Research. 2019; 71:717-734.

2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Ringold, S; Angeles-Han, ST; Beukelman, T; Lovell, D; Cuello, CA; Becker, ML; Colbert, RA; Feldman, BM; Ferguson, PJ; Gewanter, H; et al. Arthritis and Rheumatology. 2019; 71:846-863.

American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus. Brunner, HI; Holland, MJ; Beresford, MW; Ardoin, SP; Appenzeller, S; Silva, CA; Flores, F; Aydin, PO A; Wenderfer, SE; Levy, DM; et al. Arthritis Care and Research. 2019; 71:579-590.